Compare CASH & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | HROW |
|---|---|---|
| Founded | 1954 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1996 | 2008 |
| Metric | CASH | HROW |
|---|---|---|
| Price | $83.68 | $40.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $107.50 | $69.86 |
| AVG Volume (30 Days) | 167.3K | ★ 539.0K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ 6.29 | N/A |
| Revenue | ★ $839,894,000.00 | N/A |
| Revenue This Year | $7.56 | $31.62 |
| Revenue Next Year | $6.02 | $50.77 |
| P/E Ratio | $13.35 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $65.93 | $28.54 |
| 52 Week High | $101.26 | $54.98 |
| Indicator | CASH | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 53.97 |
| Support Level | $80.30 | $40.65 |
| Resistance Level | $85.41 | $42.11 |
| Average True Range (ATR) | 1.59 | 1.96 |
| MACD | -0.54 | 0.26 |
| Stochastic Oscillator | 12.41 | 68.13 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.